Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer immunology research

• Publication date

  2015-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-15-0103-TPMID 26141620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion

  2014cited by this paper
• Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens

  2014cited by this paper
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014cited by this paper
• A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

  2013cited by this paper
• SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

  2013cited by this paper
• Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Adoptive immunotherapy for cancer: harnessing the T cell response

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012influential reference
• The role of interleukin-2 during homeostasis and activation of the immune system

  2012cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Features of responding T cells in cancer and chronic infection.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Immune infiltration in human tumors: a prognostic factor that should not be ignored

  2010cited by this paper
• Toll-Like Receptor Agonists: Are They Good Adjuvants?

  2010cited by this paper
• T cell activation.

  2009cited by this paper
• CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells

  2007cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes

  2006cited by this paper
• Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4

  2005cited by this paper
• Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus.

  2004cited by this paper
• Construction of Recombinant Vaccinia Virus

  2004cited by this paper
• Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function

  2004cited by this paper
• Faculty Opinions recommendation of Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function.

  2003cited by this paper
• Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model

  2003cited by this paper
• Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells

  2003cited by this paper
• In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1

  2003cited by this paper
• Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

  2003cited by this paper
• IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells1

  2002cited by this paper
• Interleukin-12 in anti-tumor immunity and immunotherapy.

  2002cited by this paper
• CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination

  2001cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• Prostate cancer in a transgenic mouse.

  1995cited by this paper
• Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum

  1995cited by this paper
• Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen

  1995influential reference
• T cell receptor antagonist peptides induce positive selection.

  1994cited by this paper
• T-cell activation.

  1992cited by this paper
• Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen

  1989cited by this paper
• Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

  1985cited by this paper

• Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

  2018cites this paper
• Radiotherapy supports tumor-specific immunity by acute inflammation

  2016cites this paper
• Anti-CD40/Anti-CD40L

  2016cites this paper